The TRAIL apoptotic pathway in cancer onset, progression and therapy
作者： Ricky W. Johnstone , Ailsa J. Frew , Mark J. Smyth
DOI: 10.1038/NRC2465
关键词:
摘要: Triggering of tumour cell apoptosis is the foundation many cancer therapies. Death receptors necrosis factor (TNF) superfamily have been largely characterized, as signals that are generated when these activated. TNF-related apoptosis-inducing ligand (TRAIL) (TRAILR1 and TRAILR2) promising targets for therapy. Herein we review what known about molecular control TRAIL-mediated apoptosis, role TRAIL in carcinogenesis potential therapeutic utility recombinant agonistic antibodies against TRAILR1 TRAILR2.
nature.com
uq.edu.au参考文章(224)
Mark J Smyth, Kazuyoshi Takeda, Yoshihiro Hayakawa, Jacques J Peschon, Marcel R.M van den Brink, Hideo Yagita, Nature's TRAIL: On a path to cancer immunotherapy Immunity. ,vol. 18, pp. 1- 6 ,(2003) , 10.1016/S1074-7613(02)00502-2
Sinead A. Keogh, Henning Walczak, Lisa Bouchier-Hayes, Seamus J. Martin, Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis. FEBS Letters. ,vol. 471, pp. 93- 98 ,(2000) , 10.1016/S0014-5793(00)01375-2
Fei Guo, Celia Sigua, Jianguo Tao, Purva Bali, Prince George, Yunqing Li, Sylvie Wittmann, Lynn Moscinski, Peter Atadja, Kapil Bhalla, Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells Cancer Research. ,vol. 64, pp. 2580- 2589 ,(2004) , 10.1158/0008-5472.CAN-03-2629
Ki M Kim, Yong J Lee, Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the P13K-Akt pathway Oncogene. ,vol. 24, pp. 355- 366 ,(2005) , 10.1038/SJ.ONC.1208213
E Mori, M Thomas, K Motoki, K Nakazawa, T Tahara, K Tomizuka, I Ishida, S Kataoka, Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death & Differentiation. ,vol. 11, pp. 203- 207 ,(2004) , 10.1038/SJ.CDD.4401331
Eugene Varfolomeev, John W. Blankenship, Sarah M. Wayson, Anna V. Fedorova, Nobuhiko Kayagaki, Parie Garg, Kerry Zobel, Jasmin N. Dynek, Linda O. Elliott, Heidi J.A. Wallweber, John A. Flygare, Wayne J. Fairbrother, Kurt Deshayes, Vishva M. Dixit, Domagoj Vucic, IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. ,vol. 131, pp. 669- 681 ,(2007) , 10.1016/J.CELL.2007.10.030
M. J. Smyth, M. W.L. Teng, J. Sharkey, J. A. Westwood, N. M. Haynes, H. Yagita, K. Takeda, P. V. Sivakumar, M. H. Kershaw, Interleukin 21 enhances antibody-mediated tumor rejection. Cancer Research. ,vol. 68, pp. 3019- 3025 ,(2008) , 10.1158/0008-5472.CAN-07-6019
Olaf Hoffmann, Josef Priller, Timour Prozorovski, Ulf Schulze-Topphoff, Nevena Baeva, Jan D. Lunemann, Orhan Aktas, Cordula Mahrhofer, Sarah Stricker, Frauke Zipp, Joerg R. Weber, TRAIL limits excessive host immune responses in bacterial meningitis. Journal of Clinical Investigation. ,vol. 117, pp. 2004- 2013 ,(2007) , 10.1172/JCI30356
Raymond A DANIELS, Helen TURLEY, Fiona C KIMBERLEY, Xue Song LIU, Juthathip MONGKOLSAPAYA, Paul CH'EN, Xiao Ning XU, Boquan JIN, Francesco PEZZELLA, Gavin R SCREATON, Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Research. ,vol. 15, pp. 430- 438 ,(2005) , 10.1038/SJ.CR.7290311
R. K. Lindemann, A. Newbold, K. F. Whitecross, L. A. Cluse, A. J. Frew, L. Ellis, S. Williams, A. P. Wiegmans, A. E. Dear, C. L. Scott, M. Pellegrini, A. Wei, V. M. Richon, P. A. Marks, S. W. Lowe, M. J. Smyth, R. W. Johnstone, Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma Proceedings of the National Academy of Sciences of the United States of America. ,vol. 104, pp. 8071- 8076 ,(2007) , 10.1073/PNAS.0702294104